|
Age (years)
|
60 ± 5
|
58 ± 6
|
0.237
|
|
Male (n,%)
|
19 (46.3)
|
9 (31.0)
|
0.149
|
|
Body-mass index (kg/m2)
|
25.7 ± 3.3
|
26.4 ± 3.6
|
0.468
|
|
SBP (mmHg)
|
131 ± 18
|
122 ± 17
|
0.066
|
|
DBP(mmHg)
|
74 ± 10
|
71 ± 8
|
0.305
|
|
Diabetes duration (years)
|
9.1 ± 7.1
|
8.7 ± 6.1
|
0.813
|
|
Hypertension (n,%)
|
29 (70.7)
|
19 (65.5)
|
0.418
|
|
Dyslipidemia (n,%)
|
18 (62.1)
|
27 (65.9)
|
0.47
|
|
Family history of CAD (n,%)
|
25 (61.0)
|
17 (58.6)
|
0.519
|
|
Smoking Hx (n,%)
| | |
0.064
|
|
Never smoker
|
29 (70.7)
|
25 (86.2)
| |
|
Ex-smoker
|
4 (9.8)
|
3 (10.3)
| |
|
Current smoker
|
8 (19.5)
|
1 (3.4)
| |
|
FPG (mg/dL)
|
132 ± 46
|
136 ± 41
|
0.718
|
|
PPG-2 hrs (mg/dL)
|
219 ± 104
|
196 ± 90
|
0.331
|
|
HbA1c (%)
|
7.49 ± 1.24
|
7.14 ± 1.19
|
0.398
|
|
GA (%)
|
19.7 ± 6.8
|
18.4 ± 4.9
|
0.362
|
|
hsCRP (mg/dL)
|
2.75 ± 5.39
|
1.83 ± 2.23
|
0.335
|
|
Total cholesterol (mg/dL)
|
175 ± 50
|
166 ± 43
|
0.414
|
|
LDL cholesterol (mg/dL)
|
100 ± 37
|
94 ± 39
|
0.585
|
|
HDL cholesterol (mg/dL)
|
45 ± 11
|
46 ± 12
|
0.745
|
|
TG (mg/dL)
|
130 ± 76
|
118 ± 44
|
0.41
|
|
Postprandial TG (mg/dL)
|
124 ± 60
|
112 ± 43
|
0.352
|
|
HOMAIR
|
5.25 ± 6.51
|
4.18 ± 3.10
|
0.364
|
|
Framingham risk score (FRS)
|
7.3 ± 5.6
|
5.2 ± 6.3
|
0.18
|
|
CACS
|
206 ± 342
|
3 ± 13
|
0.003
|
|
Chemerin (ng/mL)
|
201.3 ± 82.3
|
193.1 ± 75.9
|
0.674
|
|
Omentin (ng/mL)
|
104.4 ± 29.4
|
106.4 ± 23.5
|
0.767
|
|
YKL-40 (ng/mL)
|
148.6 ± 82.3
|
96.7 ± 73.0
|
0.013
|
|
sCD26 (ng/mL)
|
381.5 ± 399.4
|
332.0 ± 188.9
|
0.494
|
|
Insulin (%)
|
12 (29.3)
|
9 (31.0)
|
0.54
|
|
Sulfonylurea (%)
|
18 (43.9)
|
14 (48.3)
|
0.453
|
|
Metformin (%)
|
29 (70.7)
|
24 (82.8)
|
0.192
|
|
Thiazolidinedione (%)
|
12 (29.3)
|
7 (24.1)
|
0.423
|
|
ARB or ACE inhibitors (%)
|
26 (63.4)
|
12 (41.4)
|
0.057
|
|
Calcium channer blockers (%)
|
10 (24.4)
|
6 (20.7)
|
0.474
|
|
Beta blockers (%)
|
5 (12.2)
|
2 (6.9)
|
0.381
|
|
Statins (%)
|
22 (53.7)
|
15 (51.7)
|
0.533
|
